Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 31

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 31
---
 in such jurisdiction.

### MARKET AND INDUSTRY DATA
Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Denali’s and Semnur’s own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this proxy statement/prospectus, we have not independently verified the market and industry data contained in this proxy statement/prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the information provided in this proxy statement/prospectus.

### TRADEMARKS
This document contains references to trademarks, trade names and service marks belonging to other entities. Solely for convenience, trademarks, trade names and service marks referred to in this proxy statement/prospectus may appear without the or TM symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

<div align='center'>viii</div>

TABLE OF CONTENTS

|                                                                                                                      |     | PAGE |     |
| FREQUENTLY USED TERMS                                                                                                |     |      |   1 |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS                                                                 |     |      |   5 |
| QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION AND THE MEETING                                                 |     |      |   7 |
| SUMMARY OF THE PROXY STATEMENT                                                                                       |     |      |  34 |
| The Parties to the Business Combination                                                                              |     |      |  34 |
| The Merger Agreement                                                                                                 |     |      |  37 |
| Certain Related Agreements and Arrangements                                                                          |     |      |  43 |
| Interests of Certain Persons in the Business Combination                                                             |     |      |  46 |
| Compensation Received or to be Received by, and Securities Issued or to be Issued to, the Sponsor and its Affiliates |     |      |  50 |
| Material Financing Transactions in connection with the Business Combination                                          |     |      |  53 |
| Restrictions